Q: Eptifibatide, glycoprotein IIb/IIIa inhibitor, which is frequently used in acute coronary syndrome and during PCI (percutaneous coronary intervention) is contraindicated in which population of patients?

Answer: Hemodialysis (HD) dependent patients

Safety of eptifibatide is not established in HD patients and so should be use with extreme caution, if absolutely necessary.

Patients who have creatinine clearance <50 mL/min, the recommended dose is an intravenous bolus of 180 µg/kg, immediately followed by a continuous infusion of 1.0 µg/kg/min, which is half of normal infusion dose. Second IV bolus of 180 µg/kg is usually given after 10 minutes of first bolus.